Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Ex Input:
His two attempts to craft legislation replacing Obama’s law have collapsed for lack of GOP support. Republican opposition seems likely to doom a vote next week on his Plan C, a bill simply repealing much of Obama’s statute. Along the way, conservative Sen. Ron Johnson, R-Wis., accused McConnell of a “serious breach of trust” by telling moderates that proposed Medicaid cuts would not occur. His fellow Kentucky Republican, Sen. Rand Paul, was a constant thorn and the most vociferous opponent of McConnell’s effort. And Utah Sen. Mike Lee, R-Utah, gave party leaders little advance word when he and Sen. Jerry Moran, R-Kansas, deserted the bill late Monday, effectively killing it in the dark of night. “This has been a very, very challenging experience for all of us,” McConnell told reporters Tuesday. McConnell faced a difficult environment. Polls have consistently shown Obama’s statute was far more popular than the GOP effort to repeal it, making his bill a tough sell to colleagues. President Donald Trump’s dismal approval ratings and zigzagging engagement haven’t helped. And facing unbroken Democratic opposition, McConnell needed to win over at least 50 of the 52 GOP senators, a .962 batting average he’s been unable to achieve. “Mitch has a tough, tough job and frankly I cut him a lot of slack on this. He can only do so much,” said Sen. Jeff Flake, R-Ariz. Democrats, who often grudgingly marvel at McConnell’s moves, kept waiting for him to pull a rabbit from what turned out to be an empty hat. They said he overreached by turning a bill reshaping Obama’s law into one that also cut nearly $1 trillion in taxes over a decade and sliced almost $800 billion from Medicaid, the health care program for the poor, disabled and nursing home patients. They say he boxed himself in by rushing to deliver on his party’s seven-year-old overpromise to repeal Obama’s law. That proved an arduous task that angered tens of millions who’ve benefited from the statute, especially with much of McConnell’s work performed behind closed office doors. “I don’t have any sympathy for him,” said Sen. Richard Durbin, D-Ill., his party’s No. 2 Senate leader. “I assume he felt duty-bound as the Republican leader” to pursue repeal of Obama’s law. But he said McConnell should have known that “rewriting the health care system of America on the fly and in secret was not going to work.” McConnell seemed to be trying to turn lemons into lemonade with next week’s likely rejection of a simple repeal of much of Obama’s law. By losing, GOP leaders would send a message to conservative voters that they tried to obliterate the law, while signaling to Republican senators that the votes aren’t there and it is time to move on. A senator for 33 years, the 75-year-old McConnell has a reputation for weaving compromises that avert onrushing political disasters. He cut several such deals during Obama’s years in the White House, including major budget pacts in 2011 and 2013. But once Donald Trump won the presidency and Republicans took House and Senate control this year, it became McConnell’s job to play offense. In particular, he is quarterback of the Senate GOP drive to repeal Obama’s law. But dismantling the law is not going to happen, at least in the immediate future. Assessing Democrats as unwilling to help them scrap Obama’s law — which they were — McConnell ignored them from the start. That tactic ignored his own advice from his 2016 memoir, “The Long Game,” in which he criticized Democrats for passing Obama’s 2010 statute “without regard for the views of the other side.” “Once you only have 52 votes and you try to do a bill just with Republicans, you set yourself up for a nearly impossible task,” said Senate Minority Leader Chuck Schumer, D-N.Y. McConnell’s latest bill would cut Medicaid, letting insurers sell policies with negligible coverage and rolling back Obama taxes on the health care industry. Getting GOP votes for it is a Rubik’s cube-like problem because conservatives and moderates have mutually exclusive demands, like whether to slash Medicaid or erase Obama regulations protecting consumers. “You have first- and second-term twerps that think they know the solution to everything,” said former Senate Majority Leader Trent Lott, R-Miss., who retired in 2007. “This was always going to be a difficult process and I’m not sure how we would have handled it differently,” said No. 2 Senate GOP leader John Cornyn of Texas. Movement conservatives who have often accused McConnell of not being an aggressive enough champion of their causes do fault him. “Mitchcare collapses,” read a statement by Ken Cuccinelli, who heads the Senate Conservatives Fund, which has clashed with McConnell. Cuccinelli called the bill’s demise “an embarrassing defeat for someone who portrays himself as a strategic genius.”

Ex Output:
Crumbling health bill dents McConnell image as top tactician.


Ex Input:
Tuberculosis is North Korea’s biggest public health problem. With this American-made machine, his lab would be able to complete a TB test in just two hours, instead of two months. It took years, but Dr. O got the machines, only to discover that GeneXpert needs cartridges he can’t replace. It’s not entirely clear what about the cartridges would violate international sanctions. For a long time, the producer refused to disclose what agents were inside because that was patented information. But it doesn’t really matter. No one, it seems, is willing to help him procure them from abroad and run the risk of angering Washington. Despite a budding mood of detente on the Korean Peninsula since the summit between President Donald Trump and North Korean leader Kim Jong Un last month in Singapore, ongoing sanctions championed by the U.S. and Trump’s “maximum pressure” policy continue to generate an atmosphere of hesitation and the fear of even unintentional violations. And that is keeping lifesaving medicines and supplies from thousands of North Korean tuberculosis patients. Dr. O’s laboratory, built with help from Stanford University and Christian Friends of Korea aid group, has essentially been running on empty since April. But the idle GeneXperts may soon be the least of his troubles. ___ Tuberculosis kills more than 1.6 million people a year. When left untreated it will be fatal in half of those it infects. It’s the world’s most deadly infectious disease and is so contagious that each case can be expected to lead to 10 to 20 more. In developed countries, it has largely been brought under control. There’s a vaccine that prevents it and a cocktail of drugs that can be used to treat, and often cure, it in a matter of months. But it’s a major scourge in less affluent places, including North Korea and sub-Saharan Africa. To help North Korea control its tuberculosis problem, a Geneva-based international aid organization called the Global Fund to Fight AIDS, Tuberculosis and Malaria has dispersed more than $100 million in grants since 2010. Last year it supported the treatment of about 190,000 North Korean TB patients. But, two weeks ago, Global Fund ended all of its North Korea-related grants, saying it could no longer accept the North’s “unique operating conditions.” Spokesman Seth Faison said the fund informed Pyongyang in February so it would have time to look for alternative funding sources. He said Global Fund is providing buffer stocks of medicines and health products to help support the treatment of tuberculosis patients through June next year. Faison said Global Fund welcomes the “positive diplomatic efforts underway” between Pyongyang and its neighbors. But the fund’s position stands. The decision shocked the doctors at the Pyongyang tuberculosis lab, who praised Global Fund for the work it had done but accused it of bowing to political pressure from the United States and Trump’s vow to keep the pressure on and not ease sanctions until the North makes major steps toward denuclearization. The United States government, which has pledged $1.4 billion this year, is one of Global Fund’s biggest donors. The fund’s retreat sparked outrage outside of North Korea as well. In an open letter published in the medical journal Lancet, Harvard physician Kee Park, director of North Korea programs for the Korean American Association, warned the fund’s withdrawal could create a “humanitarian and public health crisis” and called the move “a cataclysmic betrayal of the people of the DPRK.” Whatever the reason, its departure is valid cause for concern. When tuberculosis patients reduce or go off their medications prematurely, or begin taking lower quality ones, the bacteria that causes their disease can develop a resistance to the two most powerful anti-TB drugs, making the condition harder and much more expensive to treat. This kind of multi-drug resistant TB is most often found in China, India and Russia. And it’s a big problem in North Korea. ___ North Korea’s health system is fragile and strapped for resources. But in keeping with Kim’s directives to lift the nation’s standard of living, officials are looking for ways to improve. “We have been waging a vigorous struggle with a highly ambitious plan to increase the average life expectancy of the population and bring other health indices in line with those of the world’s most advanced countries,” explained Ri Jong Chang, who is the director of the Central Tuberculosis Prevention Institute and has worked with TB patients for the past 25 years. Ri explained that at the most basic level, the country maintains a network of about 7,000 clinics and a system initiated decades ago that focuses on “household doctors.” Each doctor is responsible for the care of 150 households within their administrative area. Along with primary care, they keep their patients informed and educated about health issues and conduct activities to prevent diseases. If a suspected case of tuberculosis is found, the patient is sent to a county-level hospital for testing. Aware of its needs and vulnerabilities, North Korea, which is generally secretive and deeply suspicious of anything that smacks of foreign “meddling,” has demonstrated a surprising willingness to accept help, allow access and share information with United Nations’ agencies and foreign aid organizations. Along with Global Fund, the most established group treating TB patients in the North is the Eugene Bell Foundation, which supports the treatment of more than 1,000 patients at 12 centers across the country. Unlike Global Fund, since 2008 the Eugene Bell Foundation has been solely focused on fighting multi drug-resistant tuberculosis, which typically takes about 18 months to treat and costs nearly $5,000 per patient. Stephen Linton, who founded the group in 1995, has a grim assessment of the situation. “We are probably only covering about one-tenth of the MDR-TB patients in the country right now,” he told The Associated Press. He said about half of his patients are in Pyongyang, a city of 3 million and the place where most of the North’s elites reside. The reason is straightforward — MDR-TB develops after exposure to medications that failed. In rural areas, fewer people have access to those medicines to begin with. “If you are living in the countryside in North Korea, you are much less likely to get MDR-TB than if you live in Pyongyang. It’s horrendous,” he said. “We can’t get to the bottom of it, even though we focus a lot of resources there.” What really worries him, and the North Korean government, is what will happen if the patients who relied on Global Fund support run out of medications, stop getting help or turn to cheaper, less effective treatments. Many will die. But not before infecting many others. “This is an airborne infection,” he said. “Every time you are in a closed space with a TB patient, you are at risk. So for all the people that travel to North Korea, all the tourists, all the diplomats — they are a risk to everyone who comes near them.” ___ This was supposed to be the year Eugene Bell began to really up its game in North Korea, tripling to 3,000 the number of patients it treats. Many of the sanatoria where TB patients are treated in the North were built 30 or 40 years ago. They have poor insulation, are overcrowded and are often fire hazards. To address those problems and the sort of transparency issues Global Fund was concerned about, Eugene Bell has developed pre-fabricated wards tailor-made to meet the North’s conditions. They are simple, single-story duplexes. Each can be put up quickly by three or four people, meaning the entire process can be monitored while Linton and other Eugene Bell people are in the country on their bi-annual medical team visits. The wards are already paid for when they are shipped from China, so the money isn’t going into the pockets of government officials or funding Kim Jong Un’s missile programs. The idea was to begin putting up 80-100 wards to create large centers in each of North Korea’s nine provinces. A pilot project with 10 wards is now operating on the outskirts of Pyongyang, not far from the airport. Linton said everything was going well until last December. “Then we ran into this sanctions problem,” he said. “It’s officially approved. The design is approved. And it’s not that we can’t send anything in. But these buildings have a metal roof — a panel that has metal in it, aluminum — and that’s the issue.” Linton said Eugene Bell has a quarter of a million dollars’ worth of them “rotting in monsoon weather” in a dockyard outside of Seoul. He believes that until Washington makes it clear it is not against humanitarian aid, other countries and aid organizations will be reluctant to act — or even approve the shipment of items like Dr. O’s GeneXpert cartridges or Eugene Bell’s patient wards that are clearly intended for humanitarian use. As an American, Linton says, he is concerned the U.S. will be held responsible for whatever bad happens with TB in North Korea since no country is as seen as “owning” the sanctions as much as America. “Unless something is done and done soon, this medical emergency will become known in Korea as the ‘Sanctions TB Epidemic,’” he said. “And it will haunt the peninsula for generations.” ___ Talmadge is the AP’s Pyongyang bureau chief. Follow him on Instagram and Twitter: @EricTalmadge

Ex Output:
Despite detente, sanctions on North Korea fan TB epidemic.


Ex Input:
They said drugs that blocked the enzyme glycogen synthase  kinase, or GSK3, helped mice with mixed-lineage leukemia, or  MLL, live far longer than untreated mice. The finding is a surprise because prior studies have found  GSK3 helped suppress unchecked cell growth in other cancers. “GSK3 has never been implicated in promoting cancer,” said  Dr. Michael Cleary of Stanford University in California, whose  research appears in the journal Nature. Cleary’s team found that blocking GSK3 fights leukemias  caused by mutations in the MLL gene, which accounts for 5  percent to 10 percent of child and adult leukemias and more  than three-quarters of leukemias diagnosed in infants. Cleary said only a few hundred people in the United States  get MLL each year, but when babies get leukemia, they tend to  get this form, although it is not clear why. While most leukemias get their start in either lymph nodes  or bone marrow, MLL cancer cells can originate from both. “These patients don’t typically respond well to  chemotherapy. There is a real need for better treatments,”  Cleary said in a telephone interview. His team first got a hint that blocking GSK3 might fight  MLL through routine screening tests in the lab. The researchers gave the mice with MLL lithium, a drug used  to treat bipolar disease in humans. “It is not the best GSK3 inhibitor, but it is one that  could be administered long-term in mice,” Cleary said. Mice treated with the lithium lived significantly longer  than the untreated mice. Cleary’s team also used a different  GSK3 inhibitor in MLL cells and found it stopped them from  growing. “I think where we need to go in the future is to come up  with better inhibitors that can be administered long-term,”  Cleary said. That may come through research of the drug in other  diseases. Cleary said drug companies are developing GSK3  inhibitors as treatments for diabetes and Alzheimer’s disease.

Ex Output:

Blocking enzyme could help in rare blood cancer.